The Goodpasture autoantigen. Structural delineation of two immunologically privileged epitopes on alpha3(IV) chain of type IV collagen - PubMed (original) (raw)
. 1996 Apr 12;271(15):9062-8.
doi: 10.1074/jbc.271.15.9062.
Affiliations
- PMID: 8621555
- DOI: 10.1074/jbc.271.15.9062
Free article
The Goodpasture autoantigen. Structural delineation of two immunologically privileged epitopes on alpha3(IV) chain of type IV collagen
R Kalluri et al. J Biol Chem. 1996.
Free article
Abstract
The family of type IV collagen comprises six chains numbered alpha1 through alpha6. The alpha3(IV) NC1 domain is the primary target antigen for autoantibodies from patients with anti-basement membrane disease and Goodpasture syndrome. Earlier peptide studies suggested that the last 36 amino acids of the alpha3 NC1 domain probably contains one recognition site for Goodpasture autoantibodies, and an algorithm analysis of secondary structure from a later study predicted a second possible upstream epitope near the triple helix junction. We have used several analytic approaches to evaluate the likelihood of two immunologic epitopes for the Goodpasture antigen. In our first set of studies, peptide antibodies directed against these two putative regions co-inhibited Goodpasture autoantibodies binding to denatured human alpha3(IV) NC1 monomer by nearly 80%, with the helix-junction region of the alpha3 NC1 domain contributing 26% of the binding sites and the C-terminal region contributing the remaining 50%. Second, both of these candidate regions are normally sequestered within the associated alpha3(IV) NC1 hexamer but become more visible for binding by anti-peptide antibodies upon their dissociation, a property that is shared by the Goodpasture autoantibodies. Third, segment deletions of recombinant alpha3 NC1 domain further confirmed the presence of two serologic binding sites. Finally, we looked more closely at the C-terminal binding region of the alpha3(IV) NC1 domain. Since the lysines in that region have been previously advanced as possible contact sites, we created several substitutions within the C-terminal epitope of the alpha3 NC1 domain. Substitution of lysines to alanines revealed lysines 219 and 229 as essential for antibody binding to this distal site; no lysines were present in the NC1 part of the helix-NC1 junction region. Substitutions involving arginine and cysteines to alanines in the same C-terminal region did not produce significant reductions in antibody binding. In summary, our findings characterize two Goodpasture epitopes confined to each end of the alpha3 NC1 domain; one is lysine-dependent, and the other is not. We propose, as a hypothetical model, that these two immunologically privileged regions fold to form an optimal pathogenic structure within the NC1 domain of the alpha3 chain. These sites are subsequently concealed by NC1 hexamer assembly of type IV collagen.
Similar articles
- Goodpasture antigen: expression of the full-length alpha3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain.
Leinonen A, Netzer KO, Boutaud A, Gunwar S, Hudson BG. Leinonen A, et al. Kidney Int. 1999 Mar;55(3):926-35. doi: 10.1046/j.1523-1755.1999.055003926.x. Kidney Int. 1999. PMID: 10027929 - The goodpasture autoantigen. Identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain.
Borza DB, Netzer KO, Leinonen A, Todd P, Cervera J, Saus J, Hudson BG. Borza DB, et al. J Biol Chem. 2000 Feb 25;275(8):6030-7. doi: 10.1074/jbc.275.8.6030. J Biol Chem. 2000. PMID: 10681598 - Zebrafish to humans: evolution of the alpha3-chain of type IV collagen and emergence of the autoimmune epitopes associated with Goodpasture syndrome.
MacDonald BA, Sund M, Grant MA, Pfaff KL, Holthaus K, Zon LI, Kalluri R. MacDonald BA, et al. Blood. 2006 Mar 1;107(5):1908-15. doi: 10.1182/blood-2005-05-1814. Epub 2005 Oct 27. Blood. 2006. PMID: 16254142 Free PMC article. - Molecular characterization of the target antigens of anti-glomerular basement membrane antibody disease.
Borza DB, Hudson BG. Borza DB, et al. Springer Semin Immunopathol. 2003 May;24(4):345-61. doi: 10.1007/s00281-002-0103-1. Springer Semin Immunopathol. 2003. PMID: 12778332 Review. - Molecular characteristics of the Goodpasture autoantigen.
Hudson BG, Kalluri R, Gunwar S, Noelken ME, Mariyama M, Reeders ST. Hudson BG, et al. Kidney Int. 1993 Jan;43(1):135-9. doi: 10.1038/ki.1993.22. Kidney Int. 1993. PMID: 7679455 Review.
Cited by
- Minor collagens of the skin with not so minor functions.
Theocharidis G, Connelly JT. Theocharidis G, et al. J Anat. 2019 Aug;235(2):418-429. doi: 10.1111/joa.12584. Epub 2017 Feb 2. J Anat. 2019. PMID: 31318053 Free PMC article. Review. - Crescentic Glomerulonephritis with Anti-GBM and p-ANCA Antibodies.
Javed T, Vohra P. Javed T, et al. Case Rep Nephrol. 2012;2012:132085. doi: 10.1155/2012/132085. Epub 2012 Feb 26. Case Rep Nephrol. 2012. PMID: 24527239 Free PMC article. - Cutting edge issues in Goodpasture's disease.
Chan AL, Louie S, Leslie KO, Juarez MM, Albertson TE. Chan AL, et al. Clin Rev Allergy Immunol. 2011 Oct;41(2):151-62. doi: 10.1007/s12016-010-8222-2. Clin Rev Allergy Immunol. 2011. PMID: 21207195 Review. - Angiogenesis and chronic kidney disease.
Maeshima Y, Makino H. Maeshima Y, et al. Fibrogenesis Tissue Repair. 2010 Aug 5;3:13. doi: 10.1186/1755-1536-3-13. Fibrogenesis Tissue Repair. 2010. PMID: 20687922 Free PMC article. - Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis.
Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG. Pedchenko V, et al. N Engl J Med. 2010 Jul 22;363(4):343-54. doi: 10.1056/NEJMoa0910500. N Engl J Med. 2010. PMID: 20660402 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources